Clinical Trial Update: Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH [Phase 3]

View source ↗

Summary

Phase 3 trial update on NX-1207 intraprostatic injection for LUTS due to BPH; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia
• Lower Urinary Tract Symptoms

Drugs mentioned

• NX-1207

Snippet

Sponsor: RECORDATI GROUP | Conditions: Lower Urinary Tract Symptoms | Phase 3 | Status: TERMINATED